Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3

NewMediaWire· Investor Brand Network
NewMediaWire
2 min read
0
In this article:

LOS ANGELES, CA - (NewMediaWire) - January 3, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.

  • Clene Inc., a late clinical-stage biopharmaceutical company focused on developing solutions that improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, recently announced the publication of a peer-reviewed article

  • The article describes results from two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8, the company's lead drug candidate, on brain energy metabolite levels in participants with Parkinson's Disease and Multiple Sclerosis, respectively

  • Researchers measured key brain metabolites, such as NADH and NAD+, which are involved in neuronal energy production, utilization, and maintenance, for changes from baseline with daily, oral treatment of CNM-Au8 over 12 weeks

  • Results from the studies showed that treatment with CNM-Au8 increased the brain NAD+/NADH ratio by a statistically significant (p < 0.05) 10.4%

Energy metabolism involves the conversion of the potential energy contained in food-borne fuels, including some amino acids, glucose, lactate, fatty acids, and ethanol, among others, into chemical energy. Usually, this chemical energy exists in the form of adenosine triphosphate ("ATP"), the universal energy-containing molecule that powers most cellular functions, including brain function.

ATP is produced through oxidative phosphorylation ("OXPHOS") or glycolysis. The former, however, requires mitochondria and yields considerably more ATP than the latter (https://ibn.fm/9pQ6P). Unfortunately, oxidative phosphorylation can sometimes become impaired, affecting skeletal muscle, cardiac, and nervous tissues normally characterized by high energy metabolism. Causes of the impairments to oxidative phosphorylation vary from

Read More

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

The latest news and updates relating to CLNN are available in the company's newsroom at https://ibn.fm/CLNN

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California

www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Advertisement

Recommended Stories